NDAORALTABLET
Approved
Nov 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUTAB is an oral tablet formulation combining sodium sulfate, magnesium sulfate, and potassium chloride for bowel preparation prior to colonoscopy or other GI procedures. This osmotic laxative combination works by drawing water into the intestinal lumen to cleanse the colon. It represents a tablet-based alternative to traditional liquid polyethylene glycol (PEG) solutions.
$29MPart D
Peak10.9 years to LOEProduct is at peak commercial maturity with stable Medicare utilization; commercial team likely stable or consolidating post-launch efforts.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SUTAB offers stable career opportunities within a mature, non-complex commercial franchise focused on GI specialty channels and gastroenterology practices. Career growth will center on market penetration, payer relationships, and procedural volume optimization rather than clinical trial expansion.
Brand ManagerField Sales Representative
Worked on SUTAB at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.